Dechert LLP represented XO1 Limited on its sale to Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The transaction closed on March 18.

Janssen Pharmaceuticals has acquired 100% of the shares in XO1 Limited, a privately held UK-based company developing Ichorcumab, a novel anticoagulant to treat Thrombosis that was originally discovered at Addenbrooke’s Hospital in Cambridge. XO1 was backed principally by long-standing Dechert client Index Ventures, and other shareholders included The University of Cambridge and LRM. The transaction was led by London-based corporate and securities partner Graham Defries.

The Dechert team advising XO1 Limited included Graham Defries, Andrew Harrow (Corporate and Securities, London), Tom Rayski (Intellectual Property, New York), Ed Lemanowicz (Tax, Philadelphia), Daniel Hawthorne (Tax, London) and Kenny MacLeod (London).